Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Mebix's EDC Receives CDISC Certification
August 30, 2010
- Industry-Funded Trials More Likely to Publish Favorable Results: US Study
August 30, 2010
- JMA Expresses Concern about Commercial Use of Social Security Numbering System
August 30, 2010
- DSP Screens Candidates for Lurasidone's Successors
August 30, 2010
- Korosho to Help Drug Industry Become Japan's Leading Industry: Mr Asonuma
August 30, 2010
- AnGes MG to Undertake Joint Research on siRNA with alphaGEN
August 30, 2010
- Korosho to Create 10 Million-Person DB on ADR: Mr Nagatsuma
August 30, 2010
- Nesina Jumps to No. 1 Place in GP Market: Rep Track Survey
August 30, 2010
- Korosho to Allow Reimbursement of Drugs Applied Based on Data from Public Domain
August 30, 2010
- Toxicity Study Completed for LTT Bio-Pharma's Inhalant PC-SOD
August 30, 2010
- Non-specialists Should Rely on New Anti-Epileptic Drugs: Prof. Nakasato
August 30, 2010
- Wholesalers' Gross Profit Rate below 7% for the First Time
August 30, 2010
- Korosho Invites Applicants for Development of Diaminopyridine
August 30, 2010
- Anti-IL-6 Receptor Antibody Effective for IBD: NIBIO, Osaka Univ.
August 30, 2010
- Rohto: Sales Down due to Slump of Pollinosis, Metabolic Syndrome-Related Products
August 30, 2010
- Teijin: Maintains Top Market Share for Osteoporosis Drugs
August 30, 2010
- Canakinumab, KW-0761 Designated as Orphan Drugs
August 30, 2010
- Vectibix Fails to Prolong OS in Head and Neck Cancer
August 30, 2010
- Pfizer Applies for Its 1st Generics Aiming at Listing in 2011
August 30, 2010
- Meiji Seika: Sales Up 16.6% Driven by New Drugs
August 30, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…